このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Traws Pharma マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Werner Cautreels

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	3.1yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Werner Cautreels (72 yo)

less than a year

在職期間

Dr. Werner Cautreels, Ph.D. serves as Member of Advisory Board at Thuja Capital Management B.V. He also serves as Chief Executive Officer & Director of Traws Pharma, Inc. since April 01, 2024. He has been...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Guerin	Chief Financial Officer	8.7yrs	US$745.52k	0.086% $ 8.3k
Victor Moyo	Chief Medical Officer of Oncology	1.2yrs	US$405.25k	データなし
Iain Dukes	Executive Chairman	less than a year	データなし	0.15% $ 14.1k
Werner Cautreels	CEO & Director	less than a year	データなし	データなし
Nikolay Savchuk	COO & Director	less than a year	データなし	2.09% $ 202.1k
Robert Redfield	Chief Medical Officer	less than a year	データなし	データなし
Charles Pauza	Chief Scientific Officer of Virology	less than a year	データなし	データなし

0.5yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 0T2の経営陣は経験豊富とはみなされません ( 0.2年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Iain Dukes	Executive Chairman	less than a year	データなし	0.15% $ 14.1k
Werner Cautreels	CEO & Director	less than a year	データなし	データなし
Nikolay Savchuk	COO & Director	less than a year	データなし	2.09% $ 202.1k
Jack Stover	Independent Director	8.4yrs	US$126.72k	0.00044% $ 42.6
Alan Williamson	Chairman of Scientific Advisory Board	7.8yrs	データなし	データなし
Stephen Nimer	Member of Scientific Advisory Board	19.6yrs	データなし	データなし
David Parkinson	Member of Scientific Advisory Board	no data	データなし	データなし
Ross Donehower	Member of Scientific Advisory Board	no data	データなし	データなし
George Vande Woude	Member of Scientific Advisory Board	no data	データなし	データなし
Anna Skalka	Member of Scientific Advisory Board	no data	データなし	データなし
Mary Shoemaker	Independent Director	4.4yrs	US$118.22k	0.0074% $ 716.1
Trafford Clarke	Independent Director	1.8yrs	US$104.22k	0% $ 0

3.1yrs

平均在職期間

69yo

平均年齢

経験豊富なボード: 0T2の取締役会は経験豊富であると考えられます ( 5.8年の平均在任期間)。

Traws Pharma マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Traws Pharma, Inc. Announces Board Changes

High number of new directors

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Recent updates

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2023)

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

Full year 2023 earnings released: US$0.90 loss per share (vs US$0.91 loss in FY 2022)

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

New major risk - Share price stability

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Third quarter 2023 earnings released: US$0.23 loss per share (vs US$0.26 loss in 3Q 2022)

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.19 loss in 2Q 2022)

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.20 loss in 1Q 2022)

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$0.91 loss per share (vs US$0.96 loss in FY 2021)

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors

Onconova Therapeutics, Inc. Announces Board Appointments

Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.22 loss in 3Q 2021)

Onconova Therapeutics, Inc. Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Onconova Therapeutics, Inc. Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Second quarter 2022 earnings released: EPS: US$0 (vs US$0.27 loss in 2Q 2021)

Onconova Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Onconova Therapeutics, Inc., Annual General Meeting, Aug 18, 2022

Onconova Therapeutics, Inc. Announces Executive Changes

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Onconova Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma

Onconova Therapeutics, Inc. Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces the Publication of a Preclinical Study in the Journal Molecular Cancer

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Onconova Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 11, 2021

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces Resignation of Richard C. Woodman, MD, Senior Vice President Chief Medical Officer

Onconova Therapeutics, Inc. Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

Manoj Maniar, Ph.D., Senior Vice President, Product Development departs from Onconova Therapeutics, Inc

Onconova Therapeutics Files Investigational New Drug Application for Multi-Kinase CDK4/6 Inhibitor ON 123300

Onconova Therapeutics, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Onconova Therapeutics, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14